Glutamine

"Gln" redirects here. For other uses, see GLN (disambiguation).

Not to be confused with Glutamic acid or Glutaric acid.

Glutamine

Skeletal formula of L-glutamine

Ball-and-stick model

Space-filling model

|

Names
IUPAC name

Glutamine

Other names

L-Glutamine
(levo)glutamide
2,5-Diamino-5-oxopentanoic acid
2-Amino-4-carbamoylbutanoic acid
Endari[1]

Identifiers

CAS Number

* 56-85-9 Y

3D model (JSmol)

* Interactive image
* Zwitterion: Interactive image

Abbreviations  | Gln, Q
ChEBI |

* CHEBI:28300 Y

ChEMBL |

* ChEMBL930 N

ChemSpider |

* 718 Y

EC Number |

* 200-292-1

IUPHAR/BPS

* 723

KEGG |

* C00303 Y

PubChem CID

* 738

UNII |

* 0RH81L854J Y

InChI

* InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10) Y

Key: ZDXPYRJPNDTMRX-UHFFFAOYSA-N Y

* InChI=1/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)

Key: ZDXPYRJPNDTMRX-UHFFFAOYAL

SMILES

* O=C(N)CCC(N)C(=O)O

* Zwitterion: O=C(N)CCC([NH3+])C(=O)[O-]

Properties[2]

Chemical formula

| C5H10N2O3
Molar mass | 146.146 g·mol−1
Melting point | decomposes around 185°C

Solubility in water

| soluble
Acidity (pKa)  | 2.2 (carboxyl), 9.1 (amino)

Chiral rotation ([α]D)

| +6.5º (H2O, c = 2)
Pharmacology

ATC code

| A16AA03 (WHO)

Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

N verify (what is YN ?)
Infobox references

L-glutamine oral powderNames

Trade names| Endari, Nutrestore

IUPAC name

* (S)-2,5-diamino-5-oxopentanoic acid

Clinical data
Drug class| Gastrointestinal agent
Pregnancy
category|

* US: C (Risk not ruled out)[3]

Routes of
use| By mouth
External links
AHFS/Drugs.com| Monograph
MedlinePlus| a617035
Legal
License data|

* US DailyMed: Glutamine

Legal status|

* US: ℞-only

Identifiers
CAS Number|

* 56-85-9

PubChem CID|

* 5961

DrugBank|

* DB00130

ChemSpider|

* 5746

UNII|

* 0RH81L854J

KEGG|

* D00015
* C00064

ChEBI|

* CHEBI:58359

ChEMBL|

* ChEMBL930

PDB ligand|

* GLN (PDBe, RCSB PDB)

ATC code|

* A16AA03 (WHO)

Chemical and physical data
Formula| C5H10N2O3
Molar mass| 146.15 g·mol−1
3D model (JSmol)|

* Interactive image

SMILES

* C(CC(=O)N)C(C(=O)O)N

InChI

* InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1

* Key:ZDXPYRJPNDTMRX-VKHMYHEASA-N

Glutamine (symbol Gln or Q)[4] is an α-amino acid that is used in the biosynthesis of proteins. Its side chain is similar to that of glutamic acid, except the carboxylic acid group is replaced by an amide. It is classified as a charge-neutral, polar amino acid. It is non-essential and conditionally essential in humans, meaning the body can usually synthesize sufficient amounts of it, but in some instances of stress, the body's demand for glutamine increases, and glutamine must be obtained from the diet.[5][6] It is encoded by the codons CAA and CAG.

In human blood, glutamine is the most abundant free amino acid.[7]

The dietary sources of glutamine includes especially the protein-rich foods like beef, chicken, fish, dairy products, eggs, vegetables like beans, beets, cabbage, spinach, carrots, parsley, vegetable juices and also in wheat, papaya, Brussels sprouts, celery, kale and fermented foods like miso.

## Contents

* 1 Functions
* 2 Production
* 2.1 Consumers
* 3 Uses
* 3.1 Nutrition
* 3.2 Sickle cell disease
* 3.3 Medical food
* 4 Safety
* 5 Structure
* 6 Research
* 7 See also
* 8 References
* 9 External links

## Functions[edit | edit source]

Glutamine plays a role in a variety of biochemical functions:

* Protein synthesis, as any other of the 20 proteinogenic amino acids
* Lipid synthesis, especially by cancer cells.[8]
* Regulation of acid-base balance in the kidney by producing ammonium[9]
* Cellular energy, as a source, next to glucose[10]
* Nitrogen donation for many anabolic processes, including the synthesis of purines[7]
* Carbon donation, as a source, refilling the citric acid cycle[11]
* Nontoxic transporter of ammonia in the blood circulation.[citation needed]
* Integrity of healthy intestinal mucosa, though small randomized trials have shown no benefit in Crohn’s disease.[12]

## Production[edit | edit source]

Glutamine is produced industrially using mutants of Brevibacterium flavum, which gives ca. 40 g/L in 2 days using glucose as a carbon source.[13] Glutamine is synthesized by the enzyme glutamine synthetase from glutamate and ammonia. The most relevant glutamine-producing tissue is the muscle mass, accounting for about 90% of all glutamine synthesized. Glutamine is also released, in small amounts, by the lungs and brain.[14] Although the liver is capable of relevant glutamine synthesis, its role in glutamine metabolism is more regulatory than producing, since the liver takes up large amounts of glutamine derived from the gut.[7]

### Consumers[edit | edit source]

The most eager consumers of glutamine are the cells of intestines,[7] the kidney cells for the acid-base balance, activated immune cells,[15] and many cancer cells.[8][11][16]

## Uses[edit | edit source]

### Nutrition[edit | edit source]

Glutamine is the most abundant naturally occurring, nonessential amino acid in the human body, and one of the few amino acids that can directly cross the blood–brain barrier.[7] Humans obtain glutamine through catabolism of proteins in foods they eat.[17] In states where tissue is being built or repaired, like growth of babies, or healing from wounds or severe illness, glutamine becomes conditionally essential.[17]

### Sickle cell disease[edit | edit source]

In 2017, the U.S. Food and Drug Administration (FDA) approved L-glutamine oral powder, marketed as Endari, to reduce severe complications of sickle cell disease in people aged five years and older with the disorder.[1]

The safety and efficacy of L-glutamine oral powder were studied in a randomized trial of subjects ages five to 58 years old with sickle cell disease who had two or more painful crises within the 12 months prior to enrollment in the trial.[1] Subjects were assigned randomly to treatment with L-glutamine oral powder or placebo, and the effect of treatment was evaluated over 48 weeks.[1] Subjects who were treated with L-glutamine oral powder experienced fewer hospital visits for pain treated with a parenterally administered narcotic or ketorolac (sickle cell crises), on average, compared to subjects who received a placebo (median 3 vs. median 4), fewer hospitalizations for sickle cell pain (median 2 vs. median 3), and fewer days in the hospital (median 6.5 days vs. median 11 days).[1] Subjects who received L-glutamine oral powder also had fewer occurrences of acute chest syndrome (a life-threatening complication of sickle cell disease) compared with patients who received a placebo (8.6 percent vs. 23.1 percent).[1]

Common side effects of L-glutamine oral powder include constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain.[1]

L-glutamine oral powder received orphan drug designation.[1] The FDA granted the approval of Endari to Emmaus Medical Inc.[1]

### Medical food[edit | edit source]

Glutamine is marketed as medical food and is prescribed when a medical professional believes a person in their care needs supplementary glutamine due to metabolic demands beyond what can be met by endogenous synthesis or diet.[18]

## Safety[edit | edit source]

Glutamine is safe in adults and in preterm infants.[19] Although glutamine is metabolized to glutamate and ammonia, both of which have neurological effects, their concentrations are not increased much, and no adverse neurological effects were detected.[19] The observed safe level for supplemental L-glutamine in normal healthy adults is 14 g/day.[20]

Adverse effects of glutamine have been prescribed for people receiving home parenteral nutrition and those with liver-function abnormalities.[21] Although glutamine has no effect on the proliferation of tumor cells, it is still possible that glutamine supplementation may be detrimental in some cancer types.[22]

Ceasing glutamine supplementation in people adapted to very high consumption may initiate a withdrawal effect, raising the risk of health problems such as infections or impaired integrity of the intestine.[22]

## Structure[edit | edit source]

Glutamine can exist in either of two enantiomeric forms, L-glutamine and D-glutamine. The L-form is found in nature. Glutamine contains an α-amino group which is in the protonated −NH3+ form under biological conditions and a carboxylic acid group which is in the deprotonated −COO− form, known as carboxylate, under physiological conditions.

Glutamine zwitterionic forms at neutral pH: L-glutamine (left) and D-glutamine

## Research[edit | edit source]

Consequences of glutamine depletion in critically ill individuals[23]

Glutamine mouthwash may be useful to prevent oral mucositis in people undergoing chemotherapy but intravenous glutamine does not appear useful to prevent mucositis in the GI tract.[24]

Glutamine supplementation was thought to have potential to reduce complications in people who are critically ill or who have had abdominal surgery but this was based on poor quality clinical trials.[25] Supplementation does not appear to be useful in adults or children with Crohn's disease or inflammatory bowel disease, but clinical studies as of 2016 were underpowered.[12] Supplementation does not appear to have an effect in infants with significant problems of the stomach or intestines.[26]

Some athletes use L-glutamine as supplement. Studies support the positive effects of the chronic oral administration of the supplement on the injury and inflammation induced by intense aerobic and exhaustive exercise, but the effects on muscle recovery from weight training are unclear.[27]

## See also[edit | edit source]

* Isoglutamine

## References[edit | edit source]

1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 "FDA approves new treatment for sickle cell disease". U.S. Food and Drug Administration (FDA) (Press release). 7 July 2017. Archived from the original on 14 December 2019. Retrieved 10 July 2017. This article incorporates text from this source, which is in the public domain.
2. ↑ Weast, Robert C., ed. (1981). CRC Handbook of Chemistry and Physics (62nd ed.). Boca Raton, FL: CRC Press. p. C-311. ISBN 0-8493-0462-8..
3. ↑ "Glutamine Use During Pregnancy". Drugs.com. 30 September 2019. Archived from the original on 3 August 2020. Retrieved 23 April 2020.
4. ↑ "Nomenclature and Symbolism for Amino Acids and Peptides". IUPAC-IUB Joint Commission on Biochemical Nomenclature. 1983. Archived from the original on 9 October 2008. Retrieved 5 March 2018.
5. ↑ Dietary Reference Intakes: The Essential Guide to Nutrient Requirements, published by the Institute of Medicine's Food and Nutrition Board, currently available online at "Archived copy". Archived from the original on 5 July 2014. Retrieved 14 July 2014.`{{cite web}}`: CS1 maint: archived copy as title (link)
6. ↑ Lacey, JM; Wilmore, DW (August 1990). "Is glutamine a conditionally essential amino acid?". Nutrition Reviews. 48 (8): 297–309. doi:10.1111/j.1753-4887.1990.tb02967.x. PMID 2080048.
7. ↑ 7.0 7.1 7.2 7.3 7.4 Brosnan, John T. (June 2003). "Interorgan amino acid transport and its regulation". J. Nutr. 133 (6 Suppl 1): 2068S–2072S. doi:10.1093/jn/133.6.2068S. PMID 12771367.
8. ↑ 8.0 8.1 Corbet C, Feron O (2015). "Metabolic and mind shifts: from glucose to glutamine and acetate addictions in cancer". Current Opinion in Clinical Nutrition and Metabolic Care. 18 (4): 346–353. doi:10.1097/MCO.0000000000000178. PMID 26001655. S2CID 1478014.
9. ↑ Hall, John E.; Guyton, Arthur C. (2006). Textbook of Medical Physiology (11th ed.). St. Louis, Mo: Elsevier Saunders. p. 393\. ISBN 978-0-7216-0240-0.
10. ↑ Aledo, J. C. (2004). "Glutamine breakdown in rapidly dividing cells: Waste or investment?". BioEssays. 26 (7): 778–785. doi:10.1002/bies.20063. PMID 15221859.
11. ↑ 11.0 11.1 Yuneva, M.; Zamboni, N.; Oefner, P.; Sachidanandam, R.; Lazebnik, Y. (2007). "Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells". The Journal of Cell Biology. 178 (1): 93–105. doi:10.1083/jcb.200703099. PMC 2064426. PMID 17606868.
12. ↑ 12.0 12.1 Yamamoto, T; Shimoyama, T; Kuriyama, M (8 December 2016). "Dietary and enteral interventions for Crohn's disease". Current Opinion in Biotechnology. 44: 69–73. doi:10.1016/j.copbio.2016.11.011. PMID 27940405.
13. ↑ Karlheinz Drauz, Ian Grayson, Axel Kleemann, Hans-Peter Krimmer, Wolfgang Leuchtenberger, Christoph Weckbecker (2007). "Amino Acids". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.a02_057.pub2.`{{cite encyclopedia}}`: CS1 maint: multiple names: authors list (link)
14. ↑ Newsholme, P.; Lima, M. M. R.; Procopio, J.; Pithon-Curi, T. C.; Doi, S. Q.; Bazotte, R. B.; Curi, R. (2003). "Glutamine and glutamate as vital metabolites". Brazilian Journal of Medical and Biological Research. 36 (2): 153–163. doi:10.1590/S0100-879X2003000200002. PMID 12563517.
15. ↑ Newsholme, P. (2001). "Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?". The Journal of Nutrition. 131 (9 Suppl): 2515S–2522S, discussion 2522S–4S. doi:10.1093/jn/131.9.2515S. PMID 11533304.
16. ↑ Fernandez-de-Cossio-Diaz, Jorge; Vazquez, Alexei (18 October 2017). "Limits of aerobic metabolism in cancer cells". Scientific Reports. 7 (1): 13488. Bibcode:2017NatSR...713488F. doi:10.1038/s41598-017-14071-y. ISSN 2045-2322. PMC 5647437. PMID 29044214.
17. ↑ 17.0 17.1 Watford, Malcolm (September 2015). "Glutamine and glutamate: Nonessential or essential amino acids?". Animal Nutrition. 1 (3): 119–122. doi:10.1016/j.aninu.2015.08.008. PMC 5945979. PMID 29767158.
18. ↑ "GlutaSolve, NutreStore, SYMPT-X G.I., SYMPT-X Glutamine (glutamine) Drug Side Effects, Interactions, and Medication Information on eMedicineHealth". eMedicineHealth. Archived from the original on 2 February 2017. Retrieved 24 January 2017.
19. ↑ 19.0 19.1 Garlick PJ (2001). "Assessment of the safety of glutamine and other amino acids". The Journal of Nutrition. 131 (9 Suppl): 2556S–61S. doi:10.1093/jn/131.9.2556S. PMID 11533313.
20. ↑ Shao A, Hathcock JN (2008). "Risk assessment for the amino acids taurine, L-glutamine and L-arginine". Regulatory Toxicology and Pharmacology. 50 (3): 376–99. doi:10.1016/j.yrtph.2008.01.004. PMID 18325648.
21. ↑ Buchman AL (2001). "Glutamine: commercially essential or conditionally essential? A critical appraisal of the human data". The American Journal of Clinical Nutrition. 74 (1): 25–32. doi:10.1093/ajcn/74.1.25. PMID 11451714.
22. ↑ 22.0 22.1 Holecek M (2013). "Side effects of long-term glutamine supplementation". Journal of Parenteral and Enteral Nutrition. 37 (5): 607–16. doi:10.1177/0148607112460682. PMID 22990615.
23. ↑ Stehle P, Kuhn KS (2015). "Glutamine: an obligatory parenteral nutrition substrate in critical care therapy". Biomed Res Int. 2015: 1–7. doi:10.1155/2015/545467. PMC 4606408. PMID 26495301.
24. ↑ Berretta, M; Michieli, M; Di Francia, R; Cappellani, A; Rupolo, M; Galvano, F; Fisichella, R; Berretta, S; Tirelli, U (1 January 2013). "Nutrition in oncologic patients during antiblastic treatment". Frontiers in Bioscience. 18: 120–32. doi:10.2741/4091. PMID 23276913. Archived from the original on 3 August 2020. Retrieved 23 September 2021.
25. ↑ Tao, KM; Li, XQ; Yang, LQ; Yu, WF; Lu, ZJ; Sun, YM; Wu, FX (9 September 2014). "Glutamine supplementation for critically ill adults". The Cochrane Database of Systematic Reviews (9): CD010050. doi:10.1002/14651858.CD010050.pub2. PMC 6517119. PMID 25199493.
26. ↑ Moe-Byrne, T; Brown, JV; McGuire, W (18 April 2016). McGuire, William (ed.). "Glutamine supplementation to prevent morbidity and mortality in preterm infants" (PDF). The Cochrane Database of Systematic Reviews. 4: CD001457. doi:10.1002/14651858.CD001457.pub6. PMC 7055588. PMID 27089158. Archived (PDF) from the original on 26 April 2021. Retrieved 23 September 2021.
27. ↑ Raizel, Raquel; Tirapegui, Julio (5 December 2018). "Role of glutamine, as free or dipeptide form, on muscle recovery from resistance training: a review study". Nutrire. 43 (1): 28. doi:10.1186/s41110-018-0087-9. ISSN 2316-7874. S2CID 81105808.

## External links[edit | edit source]

* Glutamine spectra Archived 31 January 2018 at the Wayback Machine acquired through mass spectroscopy
* "Glutamine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2 October 2021. Retrieved 23 September 2021.

* v
* t
* e

Other alimentary tract and metabolism products (A16)

Amino acids and derivatives|

* Ademetionine
* Betaine
* Carglumic acid
* Cysteamine
* Levocarnitine
* Levoglutamide
* Metreleptin

Enzymes|

* Amino acids: phenylalanine ammonia-lyase (Pegvaliase)

* Carbohydrate metabolism: sucrase (Sacrosidase)
* alpha-glucosidase (Alglucosidase alfa)

* Glycolipid/sphingolipid: glucocerebrosidase (Alglucerase
* Imiglucerase
* Taliglucerase alfa
* Velaglucerase alfa)
* alpha-galactosidase (Agalsidase alfa
* Agalsidase beta)

* Glycosaminoglycan: iduronidase (Laronidase)
* arylsulfatase B (Galsulfase)
* iduronate-2-sulfatase (Idursulfase)

* Lipid: lysosomal lipase (Sebelipase alfa)

* Phosphate: Asfotase alfa

Other|

* Anethole trithione
* Eliglustat
* Givosiran
* Glycerol phenylbutyrate
* Lumasiran
* Miglustat
* Nitisinone
* Sapropterin
* Sodium benzoate
* Sodium phenylacetate/sodium benzoate
* Sodium phenylbutyrate
* Teduglutide
* Trientine
* Tioctic acid
* Triheptanoin
* Uridine triacetate
* Zinc acetate

* v
* t
* e

Encoded (proteinogenic) amino acids

General topics|

* Protein
* Peptide
* Genetic code

By properties|

| Aliphatic|

* Branched-chain amino acids (Valine
* Isoleucine
* Leucine)
* Methionine
* Alanine
* Proline
* Glycine

|

Aromatic|

* Phenylalanine
* Tyrosine
* Tryptophan
* Histidine

Polar, uncharged|

* Asparagine
* Glutamine
* Serine
* Threonine

Positive charge (pKa)|

* Lysine (≈10.8)
* Arginine (≈12.5)
* Histidine (≈6.1)
* Pyrrolysine

Negative charge (pKa)|

* Aspartic acid (≈3.9)
* Glutamic acid (≈4.1)
* Selenocysteine (≈5.4)
* Cysteine (≈8.3)
* Tyrosine (≈10.1)

* Amino acids types: Encoded (proteins)
* Essential
* Non-proteinogenic
* Ketogenic
* Glucogenic
* Imino acids
* D-amino acids
* Dehydroamino acids

* v
* t
* e

Dietary supplements

Types|

* Amino acids
* Bodybuilding supplement
* Energy drink
* Energy bar
* Fatty acids
* Herbal supplements
* Minerals
* Prebiotics
* Probiotics (Lactobacillus
* Bifidobacterium)
* Protein bar
* Vitamins

Vitamins and
chemical elements
("minerals")|

* Retinol (Vitamin A)
* B vitamins
* Thiamine (B1)
* Riboflavin (B2)
* Niacin (B3)
* Pantothenic acid (B5)
* Pyridoxine (B6)
* Biotin (B7)
* Folic acid (B9)
* Cyanocobalamin (B12)
* Ascorbic acid (Vitamin C)
* Ergocalciferol and Cholecalciferol (Vitamin D)
* Tocopherol (Vitamin E)
* Naphthoquinone (Vitamin K)

* Calcium
* Choline
* Chromium
* Cobalt
* Copper
* Fluorine
* Iodine
* Iron
* Magnesium
* Manganese
* Molybdenum
* Phosphorus
* Potassium
* Selenium
* Sodium
* Sulfur
* Zinc

Other common
ingredients|

* AAKG
* β-hydroxy β-methylbutyrate
* Carnitine
* Chondroitin sulfate
* Cod liver oil
* Copper gluconate
* Creatine
* Dietary fiber
* Echinacea
* Elemental calcium
* Ephedra
* Fish oil
* Folic acid
* Ginseng
* Glucosamine
* Glutamine
* Grape seed extract
* Guarana
* Iron supplements
* Japanese honeysuckle
* Krill oil
* Lingzhi
* Linseed oil
* Lipoic acid
* Milk thistle
* Melatonin
* Red yeast rice
* Royal jelly
* Saw palmetto
* Spirulina
* St John's wort
* Taurine
* Wheatgrass
* Wolfberry
* Yohimbine
* Zinc gluconate

Related articles|

* Codex Alimentarius
* Enzyte
* Hadacol
* Herbal tea
* Nutraceutical
* Multivitamin
* Nutrition

* v
* t
* e

GABA receptor modulators

Ionotropic|

| GABAA|

* Agonists: (+)-Catechin
* Bamaluzole
* Barbiturates (e.g., phenobarbital)
* Beta-Alanine
* BL-1020
* DAVA
* Dihydromuscimol
* GABA
* Gabamide
* GABOB
* Gaboxadol (THIP)
* Homotaurine (tramiprosate, 3-APS)
* Ibotenic acid
* iso-THAZ
* iso-THIP
* Isoguvacine
* Isomuscimol
* Isonipecotic acid
* Kojic amine
* L-838,417
* Lignans (e.g., honokiol)
* Methylglyoxal
* Monastrol
* Muscimol
* Nefiracetam
* Neuroactive steroids (e.g., allopregnanolone)
* Org 20599
* PF-6372865
* Phenibut
* Picamilon
* P4S
* Progabide
* Propofol
* Quisqualamine
* SL-75102
* Taurine
* TACA
* TAMP
* Terpenoids (e.g., borneol)
* Thiomuscimol
* Tolgabide
* ZAPA

* Positive modulators (abridged; see here for a full list): α-EMTBL
* Alcohols (e.g., drinking alcohol, 2M2B)
* Anabolic steroids
* Avermectins (e.g., ivermectin)
* Barbiturates (e.g., phenobarbital)
* Benzodiazepines (e.g., diazepam)
* Bromide compounds (e.g., potassium bromide)
* Carbamates (e.g., meprobamate)
* Carbamazepine
* Chloralose
* Chlormezanone
* Clomethiazole
* Dihydroergolines (e.g., ergoloid (dihydroergotoxine))
* Etazepine
* Etifoxine
* Fenamates (e.g., mefenamic acid)
* Flavonoids (e.g., apigenin, hispidulin)
* Fluoxetine
* Flupirtine
* Imidazoles (e.g., etomidate)
* Kava constituents (e.g., kavain)
* Lanthanum
* Loreclezole
* Monastrol
* Neuroactive steroids (e.g., allopregnanolone, cholesterol, THDOC)
* Niacin
* Nicotinamide (niacinamide)
* Nonbenzodiazepines (e.g., β-carbolines (e.g., abecarnil), cyclopyrrolones (e.g., zopiclone), imidazopyridines (e.g., zolpidem), pyrazolopyrimidines (e.g., zaleplon))
* Norfluoxetine
* Petrichloral
* Phenols (e.g., propofol)
* Phenytoin
* Piperidinediones (e.g., glutethimide)
* Propanidid
* Pyrazolopyridines (e.g., etazolate)
* Quinazolinones (e.g., methaqualone)
* Retigabine (ezogabine)
* ROD-188
* Skullcap constituents (e.g., baicalin)
* Stiripentol
* Sulfonylalkanes (e.g., sulfonmethane (sulfonal))
* Topiramate
* Valerian constituents (e.g., valerenic acid)
* Volatiles/gases (e.g., chloral hydrate, chloroform, diethyl ether, paraldehyde, sevoflurane)

* Antagonists: Bicuculline
* Coriamyrtin
* Dihydrosecurinine
* Gabazine (SR-95531)
* Hydrastine
* Hyenachin (mellitoxin)
* PHP-501
* Pitrazepin
* Securinine
* Sinomenine
* SR-42641
* SR-95103
* Thiocolchicoside
* Tutin

* Negative modulators: 1,3M1B
* 3M2B
* 11-Ketoprogesterone
* 17-Phenylandrostenol
* α5IA (LS-193,268)
* β-CCB
* β-CCE
* β-CCM
* β-CCP
* β-EMGBL
* Anabolic steroids
* Amiloride
* Anisatin
* β-Lactams (e.g., penicillins, cephalosporins, carbapenems)
* Basmisanil
* Bemegride
* Bicyclic phosphates (TBPS, TBPO, IPTBO)
* BIDN
* Bilobalide
* Bupropion
* CHEB
* Chlorophenylsilatrane
* Cicutoxin
* Cloflubicyne
* Cyclothiazide
* DHEA
* DHEA-S
* Dieldrin
* (+)-DMBB
* DMCM
* DMPC
* EBOB
* Etbicyphat
* FG-7142 (ZK-31906)
* Fiproles (e.g., fipronil)
* Flavonoids (e.g., amentoflavone, oroxylin A)
* Flumazenil
* Fluoroquinolones (e.g., ciprofloxacin)
* Flurothyl
* Furosemide
* Golexanolone
* Iomazenil (123I)
* IPTBO
* Isopregnanolone (sepranolone)
* L-655,708
* Laudanosine
* Leptazol
* Lindane
* MaxiPost
* Morphine
* Morphine-3-glucuronide
* MRK-016
* Naloxone
* Naltrexone
* Nicardipine
* Nonsteroidal antiandrogens (e.g., apalutamide, bicalutamide, enzalutamide, flutamide, nilutamide)
* Oenanthotoxin
* Pentylenetetrazol (pentetrazol)
* Phenylsilatrane
* Picrotoxin (i.e., picrotin, picrotoxinin and dihydropicrotoxinin)
* Pregnenolone sulfate
* Propybicyphat
* PWZ-029
* Radequinil
* Ro 15-4513
* Ro 19-4603
* RO4882224
* RO4938581
* Sarmazenil
* SCS
* Suritozole
* TB-21007
* TBOB
* TBPS
* TCS-1105
* Terbequinil
* TETS
* Thujone
* U-93631
* Zinc
* ZK-93426

|

GABAA-ρ|

* Agonists: BL-1020
* CACA
* CAMP
* Homohypotaurine
* GABA
* GABOB
* Ibotenic acid
* Isoguvacine
* Muscimol
* N4-Chloroacetylcytosine arabinoside
* Picamilon
* Progabide
* TACA
* TAMP
* Thiomuscimol
* Tolgabide

* Positive modulators: Allopregnanolone
* Alphaxolone
* ATHDOC
* Lanthanides

* Antagonists: (S)-2-MeGABA
* (S)-4-ACPBPA
* (S)-4-ACPCA
* 2-MeTACA
* 3-APMPA
* 4-ACPAM
* 4-GBA
* cis-3-ACPBPA
* CGP-36742 (SGS-742)
* DAVA
* Gabazine (SR-95531)
* Gaboxadol (THIP)
* I4AA
* Isonipecotic acid
* Loreclezole
* P4MPA
* P4S
* SKF-97541
* SR-95318
* SR-95813
* TPMPA
* trans-3-ACPBPA
* ZAPA

* Negative modulators: 5α-Dihydroprogesterone
* Bilobalide
* Loreclezole
* Picrotoxin (picrotin, picrotoxinin)
* Pregnanolone
* ROD-188
* THDOC
* Zinc

Metabotropic|

| GABAB|

* Agonists: 1,4-Butanediol
* 4-Fluorophenibut
* Aceburic acid
* Arbaclofen
* Arbaclofen placarbil
* Baclofen
* BL-1020
* GABA
* Gabamide
* GABOB
* GBL
* GHB
* GHBAL
* GHV
* GVL
* Isovaline
* Lesogaberan
* Phenibut
* Picamilon
* Progabide
* Sodium oxybate
* SKF-97,541
* SL 75102
* Tolgabide
* Tolibut

* Positive modulators: ADX-71441
* BHF-177
* BHFF
* BSPP
* CGP-7930
* CGP-13501
* GS-39783
* rac-BHFF
* KK-92A

* Antagonists: 2-Hydroxysaclofen
* CGP-35348
* CGP-46381
* CGP-52432
* CGP-54626
* CGP-55845
* CGP-64213
* DAVA
* Homotaurine (tramiprosate, 3-APS)
* Phaclofen
* Saclofen
* SCH-50911
* SKF-97541

* Negative modulators: Compound 14

|

See also
Receptor/signaling modulators
GABAA receptor positive modulators
GABA metabolism/transport modulators

Glutamate receptor modulators

* v
* t
* e

Ionotropic glutamate receptor modulators

AMPAR|

* Agonists: Main site agonists: 5-Fluorowillardiine
* Acromelic acid (acromelate)
* AMPA
* BOAA
* Domoic acid
* Glutamate
* Ibotenic acid
* Proline
* Quisqualic acid
* Willardiine; Positive allosteric modulators: Aniracetam
* BIIB-104 (PF-04958242)
* Cyclothiazide
* CX-516
* CX-546
* CX-614
* Farampator (CX-691, ORG-24448)
* CX-717
* CX-1739
* CX-1942
* Diazoxide
* Hydrochlorothiazide (HCTZ)
* IDRA-21
* LY-392098
* LY-395153
* LY-404187
* LY-451646
* LY-503430
* Mibampator (LY-451395)
* Nooglutyl
* ORG-26576
* Oxiracetam
* PEPA
* Piracetam
* Pramiracetam
* S-18986
* Tulrampator (S-47445, CX-1632)

* Antagonists: ACEA-1011
* ATPO
* Becampanel
* Caroverine
* CNQX
* Dasolampanel
* DNQX
* Fanapanel (MPQX)
* GAMS
* Kaitocephalin
* Kynurenic acid
* Kynurenine
* Licostinel (ACEA-1021)
* NBQX
* PNQX
* Selurampanel
* Tezampanel
* Theanine
* Topiramate
* YM90K
* Zonampanel; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
* Cyclopropane
* Enflurane
* Ethanol (alcohol)
* Evans blue
* GYKI-52466
* GYKI-53655
* Halothane
* Irampanel
* Isoflurane
* Perampanel
* Pregnenolone sulfate
* Sevoflurane
* Talampanel; Unknown/unsorted antagonists: Minocycline

KAR|

* Agonists: Main site agonists: 5-Bromowillardiine
* 5-Iodowillardiine
* Acromelic acid (acromelate)
* AMPA
* ATPA
* Domoic acid
* Glutamate
* Ibotenic acid
* Kainic acid
* LY-339434
* Proline
* Quisqualic acid
* SYM-2081; Positive allosteric modulators: Cyclothiazide
* Diazoxide
* Enflurane
* Halothane
* Isoflurane

* Antagonists: ACEA-1011
* CNQX
* Dasolampanel
* DNQX
* GAMS
* Kaitocephalin
* Kynurenic acid
* Licostinel (ACEA-1021)
* LY-382884
* NBQX
* NS102
* Selurampanel
* Tezampanel
* Theanine
* Topiramate
* UBP-302; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
* Enflurane
* Ethanol (alcohol)
* Evans blue
* NS-3763
* Pregnenolone sulfate

NMDAR|

* Agonists: Main site agonists: AMAA
* Aspartate
* Glutamate
* Homocysteic acid (L-HCA)
* Homoquinolinic acid
* Ibotenic acid
* NMDA
* Proline
* Quinolinic acid
* Tetrazolylglycine
* Theanine; Glycine site agonists: β-Fluoro-D-alanine
* ACBD
* ACC (ACPC)
* ACPD
* AK-51
* Apimostinel (NRX-1074)
* B6B21
* CCG
* D-Alanine
* D-Cycloserine
* D-Serine
* DHPG
* Dimethylglycine
* Glycine
* HA-966
* L-687414
* L-Alanine
* L-Serine
* Milacemide
* Neboglamine (nebostinel)
* Rapastinel (GLYX-13)
* Sarcosine; Polyamine site agonists: Neomycin
* Spermidine
* Spermine; Other positive allosteric modulators: 24S-Hydroxycholesterol
* DHEA (prasterone)
* DHEA sulfate (prasterone sulfate)
* Epipregnanolone sulfate
* Pregnenolone sulfate
* SAGE-201
* SAGE-301
* SAGE-718

* Antagonists: Competitive antagonists: AP5 (APV)
* AP7
* CGP-37849
* CGP-39551
* CGP-39653
* CGP-40116
* CGS-19755
* CPP
* Kaitocephalin
* LY-233053
* LY-235959
* LY-274614
* MDL-100453
* Midafotel (d-CPPene)
* NPC-12626
* NPC-17742
* PBPD
* PEAQX
* Perzinfotel
* PPDA
* SDZ-220581
* Selfotel; Glycine site antagonists: 4-Cl-KYN (AV-101)
* 5,7-DCKA
* 7-CKA
* ACC
* ACEA-1011
* ACEA-1328
* Apimostinel (NRX-1074)
* AV-101
* Carisoprodol
* CGP-39653
* CNQX
* D-Cycloserine
* DNQX
* Felbamate
* Gavestinel
* GV-196771
* Harkoseride
* Kynurenic acid
* Kynurenine
* L-689560
* L-701324
* Licostinel (ACEA-1021)
* LU-73068
* MDL-105519
* Meprobamate
* MRZ 2/576
* PNQX
* Rapastinel (GLYX-13)
* ZD-9379; Polyamine site antagonists: Arcaine
* Co 101676
* Diaminopropane
* Diethylenetriamine
* Huperzine A
* Putrescine; Uncompetitive pore blockers (mostly dizocilpine site): 2-MDP
* 3-HO-PCP
* 3-MeO-PCE
* 3-MeO-PCMo
* 3-MeO-PCP
* 4-MeO-PCP
* 8A-PDHQ
* 18-MC
* α-Endopsychosin
* Alaproclate
* Alazocine (SKF-10047)
* Amantadine
* Aptiganel
* Argiotoxin-636
* Arketamine
* ARL-12495
* ARL-15896-AR
* ARL-16247
* Budipine
* Coronaridine
* Delucemine (NPS-1506)
* Dexoxadrol
* Dextrallorphan
* Dextromethadone
* Dextromethorphan
* Dextrorphan
* Dieticyclidine
* Diphenidine
* Dizocilpine
* Ephenidine
* Esketamine
* Etoxadrol
* Eticyclidine
* Fluorolintane
* Gacyclidine
* Ibogaine
* Ibogamine
* Indantadol
* Ketamine
* Ketobemidone
* Lanicemine
* Levomethadone
* Levomethorphan
* Levomilnacipran
* Levorphanol
* Loperamide
* Memantine
* Methadone
* Methorphan
* Methoxetamine
* Methoxphenidine
* Milnacipran
* Morphanol
* NEFA
* Neramexane
* Nitromemantine
* Noribogaine
* Norketamine
* Orphenadrine
* PCPr
* PD-137889
* Pethidine (meperidine)
* Phencyclamine
* Phencyclidine
* Propoxyphene
* Remacemide
* Rhynchophylline
* Rimantadine
* Rolicyclidine
* Sabeluzole
* Tabernanthine
* Tenocyclidine
* Tiletamine
* Tramadol; Ifenprodil (NR2B) site antagonists:
* Besonprodil
* Buphenine (nylidrin)
* CO-101244 (PD-174494)
* Eliprodil
* Haloperidol
* Isoxsuprine
* Radiprodil (RGH-896)
* Rislenemdaz (CERC-301, MK-0657)
* Ro 8-4304
* Ro 25-6981
* Safaprodil
* Traxoprodil (CP-101606); NR2A-selective antagonists: MPX-004
* MPX-007
* TCN-201
* TCN-213; Cations: Hydrogen
* Magnesium
* Zinc; Alcohols/volatile anesthetics/related: Benzene
* Butane
* Chloroform
* Cyclopropane
* Desflurane
* Diethyl ether
* Enflurane
* Ethanol (alcohol)
* Halothane
* Hexanol
* Isoflurane
* Methoxyflurane
* Nitrous oxide
* Octanol
* Sevoflurane
* Toluene
* Trichloroethane
* Trichloroethanol
* Trichloroethylene
* Urethane
* Xenon
* Xylene; Unknown/unsorted antagonists: ARR-15896
* Bumetanide
* Caroverine
* Conantokin
* D-αAA
* Dexanabinol
* Flufenamic acid
* Flupirtine
* FPL-12495
* FR-115427
* Furosemide
* Hodgkinsine
* Ipenoxazone (MLV-6976)
* MDL-27266
* Metaphit
* Minocycline
* MPEP
* Niflumic acid
* Pentamidine
* Pentamidine isethionate
* Piretanide
* Psychotridine
* Transcrocetin (saffron)

* Unsorted: Allosteric modulators: AGN-241751

* See also: Receptor/signaling modulators
* Metabotropic glutamate receptor modulators
* Glutamate metabolism/transport modulators

* v
* t
* e

Metabotropic glutamate receptor modulators

Group I|

| mGluR1|

* Agonists: ACPD
* DHPG
* Glutamate
* Ibotenic acid
* Quisqualic acid
* Ro01-6128
* Ro67-4853
* Ro67-7476
* VU-71
* Theanine

* Antagonists: BAY 36-7620
* CPCCOEt
* Cyclothiazide
* LY-367,385
* LY-456,236
* MCPG
* NPS-2390

|

mGluR5|

* Agonists: ACPD
* ADX-47273
* CDPPB
* CHPG
* DFB
* DHPG
* Glutamate
* Ibotenic acid
* Quisqualic acid
* VU-1545

* Antagonists: CTEP
* DMeOB
* LY-344,545
* Mavoglurant
* MCPG
* NPS-2390
* Remeglurant
* SIB-1757
* SIB-1893; Negative allosteric modulators: Basimglurant
* Dipraglurant
* Fenobam
* GRN-529
* MPEP
* MTEP
* Raseglurant

Group II|

| mGluR2|

* Agonists: BINA
* CBiPES
* DCG-IV
* Eglumegad
* Glutamate
* Ibotenic acid
* LY-379,268
* LY-404,039 (pomaglumetad)
* LY-487,379
* LY-566,332
* MGS-0028
* Pomaglumetad methionil (LY-2140023)
* Talaglumetad; Positive allosteric modulators: JNJ-40411813 (ADX-71149)

* Antagonists: APICA
* CECXG
* EGLU
* HYDIA
* LY-307,452
* LY-341,495
* MCPG
* MGS-0039
* PCCG-4; Negative allosteric modulators: Decoglurant
* RO4491533

|

mGluR3|

* Agonists: CBiPES
* DCG-IV
* Eglumegad
* Glutamate
* Ibotenic acid
* LY-379,268
* LY-404,039 (pomaglumetad)
* LY-487,379
* MGS-0028
* Pomaglumetad methionil (LY-2140023)
* Talaglumetad

* Antagonists: APICA
* CECXG
* EGLU
* HYDIA
* LY-307,452
* LY-341,495
* MCPG
* MGS-0039; Negative allosteric modulators: Decoglurant
* RO4491533

Group III|

| mGluR4|

* Agonists: Glutamate
* L-AP4
* PHCCC
* VU-001,171
* VU-0155,041; Positive allosteric modulators: Foliglurax
* MPEP

* Antagonists: CPPG
* MAP4
* MPPG
* MSOP
* MTPG
* UBP-1112

|

mGluR6|

* Agonists: Glutamate
* L-AP4

* Antagonists: CPPG
* MAP4
* MPPG
* MSOP
* MTPG
* UBP-1112

mGluR7|

* Agonists: AMN082
* Glutamate
* L-AP4

* Antagonists: CPPG
* MAP4
* MMPIP
* MPPG
* MSOP
* MTPG
* UBP-1112

mGluR8|

* Agonists: DCPG
* Glutamate
* L-AP4

* Antagonists: CPPG
* MAP4
* MPPG
* MSOP
* MTPG
* UBP-1112

See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators
*[CID]: Compound ID
*[US]: United States
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template
*[GABA]: γ-Aminobutyric acid
*[GABAA]: γ-Aminobutyric acid A receptor
*[GABAA-ρ]: γ-Aminobutyric acid A-rho receptor
*[GABAB]: γ-Aminobutyric acid B receptor
*[AMPAR]: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
*[KAR]: Kainate receptor
*[NMDAR]: N-Methyl-D-aspartate receptor
*[DHEA]: Dehydroepiandrosterone
*[mGluR1]: Metabotropic glutamate receptor 1
*[mGluR5]: Metabotropic glutamate receptor 5
*[mGluR2]: Metabotropic glutamate receptor 2
*[mGluR3]: Metabotropic glutamate receptor 3
*[mGluR4]: Metabotropic glutamate receptor 4
*[mGluR6]: Metabotropic glutamate receptor 6
*[mGluR7]: Metabotropic glutamate receptor 7
*[mGluR8]: Metabotropic glutamate receptor 8